Navigation Links
Pioneer(R) Surgical Technology Announces Market Release of FortrOss(TM), a Next Generation Bone Void Filler
Date:10/14/2008

Pioneer's First In-House Biologic Product to Debut at NASS

GREENVILLE, N.C. and WOBURN, Mass., Oct. 14 /PRNewswire/ -- Pioneer Surgical Technology, Inc. today announced the U.S. market release of their FortrOss bone graft substitute. The novel biologic will make its public debut at the 23rd Annual Meeting of the North American Spine Society (NASS) in Toronto, Canada. The FortrOss bone void filler, utilizing the power of nanotechnology for orthopaedic applications, is a scaffold for the in-growth of new bone when superior bone regeneration is required.

Pioneer's CEO and Chairman of the Board, Matthew N. Songer, MD, MBA says, "The Pioneer Orthobiologics team has reached a huge milestone with the release of the FortrOss. This is the culmination of over 10 years work by each of the two companies, Encelle(TM) Inc. and Angstrom(TM) Medica, Inc. that were acquired by Pioneer in 2007."

The FortrOss bone void filler combines the nanotechnology of nanOss(TM) hydroxyapatite with the bone growth promotion of E-Matrix(TM) scaffold. The FortrOss bone void filler is the most advanced on the market. The FortrOss osteoconductive matrix utilizes Pioneer's nanOss(TM) technology and is designed to mimic the nanostructures inherent in bone tissue.

According to Dr. Edward Ahn, Vice President of Biomaterials at Pioneer states, "Because the nanOss hydroxyapatite in FortrOss resembles the size, shape, and chemistry of native bone, bone tissue has a great affinity for nanOss and recognizes it as native tissue. This mimicry of native bone makes nanOss superior to other calcium phosphates on the market."

The combined nanotechnology-based osteoconduction and osteopromotive E- Matrix scaffold of FortrOss bone void filler positions Pioneer to impact significantly the dynamic field of bone repair.

About Pioneer Surgical Technology

Pioneer Surgical Technology, Inc., headquartered in Marquette, Michigan, is a dynamic medical device firm with a full line of cutting-edge motion preservation devices, either available commercially in Europe or under clinical evaluation in the U.S. Pioneer's signature articulating P3(TM) Technology - Pioneer PEEK-on-PEEK, in its NuBac(TM) disc arthroplasty system, BacJac(TM) interspinous decompression system, and NuNec(TM) artificial cervical disc, is the most technologically advanced in the industry. Currently, Pioneer offers a diverse portfolio of next generation spinal fusion devices. Pioneer's focus on innovation has resulted in over 100 U.S. and Foreign patents with numerous patents pending. The company established a Biologics Division following two acquisitions in 2007. Pioneer Orthobiologics is developing a rich pipeline of products indicated for a variety of spinal and orthopaedic applications. Pioneer focuses on developing products which are easier and faster for the surgeon, cost effective for the health care system, and provide better patient outcomes.


'/>"/>
SOURCE Pioneer Surgical Technology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. DuPont Obtains Biotechnology Endorsement for Pioneer(R) Brand Products
2. Pioneer(R) Surgical Technology, Inc. Announces the Market Launch of the SlimFuse(TM) Anterior Cervical Plate System
3. Pioneer(R) Brand Soybeans From DuPont Deliver Step-Change in Soybean Yields
4. Pioneer(R) Surgical Technology Announces First Human Implants of its NuNec(TM) Cervical Arthroplasty Device
5. DuPont Congratulates Growers Planting Pioneer(R) Brand Sorghum Hybrids in Winning Majority of National Categories in Yield Contest
6. CryoLife Hosts Worldwide Surgical Congress for the Ross Procedure
7. Reliant Technologies Announces FDA 510(K) Clearance of New Handpieces for Skin Resurfacing and Surgical Applications
8. New Opportunities in X-Ray Based Surgical Navigation With Ziehm NaviPort 3D
9. Sound Surgical Technologies Welcomes Dr. Mark Schafer as New Chief Technology Officer and Vice President of Research & Development
10. Solos Endoscopy, Inc. Implements Strategy to Capitalize on $30 Billion Minimally Invasive Surgical Product Market
11. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... February 27, 2017 Four US ... evaluation today, and they are: Anthera Pharmaceuticals Inc. (NASDAQ: ... California Inc. (NASDAQ: PACB), and Conatus Pharmaceuticals Inc. (NASDAQ: ... ETF Trends, market observers are growing more bullish on ... enact reforms to free cash held overseas for tax ...
(Date:2/26/2017)... ... ... Rob Lowe is a well recognized television personality, so it seems natural he would ... important to the American public and important to society at large. An upcoming episode ... the world for a few years. , The climate and how we relate to ...
(Date:2/24/2017)... KNOXVILLE, Tenn. , Feb. 24, 2017 /PRNewswire/ ... ) ("Provectus" or the "Company"), a clinical-stage oncology ... information regarding the deadline to participate in its ... million units, consisting of shares of common stock ... stockholders and holders of listed warrants. ...
(Date:2/24/2017)... Staten Island, NY (PRWEB) , ... February 24, 2017 , ... ... exponential rate. Founded in late 2014, FireflySci had the goal of bringing their ... 2017, that goal continues to shape the path that FireflySci is going on as ...
Breaking Biology Technology:
(Date:2/7/2017)... MINNETONKA, Minn. , Feb. 7, 2017   ... that supports the entire spectrum of clinical research, is ... iMedNet , its innovative, highly flexible and ... iMedNet customers. iMedNet is a ... only provides Electronic Data Capture (EDC), but also delivers ...
(Date:2/6/2017)... According to Acuity Market Intelligence, ongoing ... to continue to embrace biometric and digital identification ... Border Control (ABC) eGates and 1436 Automated Passport ... 163 ports of entry across the globe. Deployments ... combined CAGR of 37%. APC Kiosks reached 75% ...
(Date:2/2/2017)... 2, 2017   TapImmune, Inc. (NASDAQ: ... specializing in the development of innovative peptide and ... cancer and metastatic disease, announced today it has ... of a second clinical lot of TPIV 200, ... alpha. The manufactured vaccine product will be used ...
Breaking Biology News(10 mins):